Phibro Animal Health's worse-than-expected Q1 results are a negative signal to investors, indicating potential operational or financial issues. Additionally, Morgan Stanley's decision to lower its price target for the stock, while maintaining an Equal-Weight rating, suggests that the investment bank sees limited upside potential in the near term. These factors are likely to put downward pressure on the stock price.